Actively Recruiting
Clinical and Laboratory Characteristics of Children and Adolescents With Newly Diagnosed Type 1 Diabetes and Insulin Requirements at Onset
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2024-12-05
180
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research investigates children and adolescents newly diagnosed with Type 1 Diabetes, focusing on clinical and laboratory factors that might predict changes in insulin sensitivity and requirements at the disease onset. The goal is to help doctors quickly find the right insulin dosage for better early metabolic control and reduce hospitalization time and costs. The study is observational and retrospective, analyzing medical records from patients diagnosed between 2014 and 2018. The study collects and reviews clinical and laboratory data from pediatric patients diagnosed with Type 1 Diabetes at a single center. It evaluates insulin needs at diagnosis, 3 months, and 12 months after onset, aiming to link these requirements with initial clinical and laboratory factors. No new treatments are given; instead, existing patient data is analyzed to understand insulin needs over time. Participants' medical records are used to track insulin dosage and laboratory results at diagnosis and during follow-up visits up to one year. The study measures insulin requirements and lab data at diagnosis, 3 months, and 12 months to identify predictive factors. There is no active treatment or intervention, and participation involves data collection only, with the study ending after data analysis.
CONDITIONS
Brief Title
Clinical and Laboratory Characteristics of a Population of Children and Adolescents With Newly Diagnosed Type 1 Diabetes and Insulin Requirements at Onset
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 14 years or younger at time of Type 1 Diabetes diagnosis
- Diagnosis of Type 1 Diabetes confirmed between January 2014 and December 2018 at the Pediatrics Unit of the IRCCS Azienda Ospedaliero-Universitaria of Bologna, Italy
- At least 1 year of follow-up after diagnosis
- Informed consent obtained from parents or legal guardians
You will not qualify if you...
- Diagnosis of diabetes other than Type 1
- Patients followed at other centers at the time of Type 1 Diabetes onset
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants who were diagnosed with Type 1 Diabetes are observed with collection and analysis of clinical and laboratory data at onset, 3 months, and 12 months after diagnosis.
3 visits (in-person) at onset, 3 months, and 12 months
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
Research Team
G
Giulio Maltoni, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here